Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...

Learn more about whether Glaukos Corporation or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Analysts have set 12-month price targets for Glaukos, revealing an average target of $170.86, a high estimate of $200.00, and ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases ...

Business may be picking up for locally-based drugmakers just a year after the local sector was showing declines.

April 09, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE ... company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases ...

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.